NeuBase Therapeutics to Present at the Stifel 2019 Healthcare Conference

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, November 12, 2019

Information

Tags:

Branches of biology, Biology, RNA, DNA, Molecular biology, Gene expression, Nucleic acids, Sense, Oligonucleotide, Gene silencing, Antisense therapy, Peptide nucleic acid

Organisation:

NEUBASE THERAPEUTICS, INC.

Summary

Key Points:

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures.
Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

PITTSBURGH, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will present a corporate overview and business update at the Stifel 2019 Healthcare Conference, which is being held from November 19th to 20th in New York City.

Event:
Date:
Time:
Webcast:

Stifel 2019 Healthcare Conference
Wednesday, November 20, 2019
10:55 a.m. EST
http://wsw.com/webcast/stifel18/nbt/

About NeuBase Therapeutics
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
OP: (617) 430-7576

NeuBase Media Contact:
Travis Kruse
Russo Partners
[email protected]
OP: (212) 845-4272

Ned Berkowitz
Russo Partners
[email protected]
OP: (646) 942-5629